- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06254248
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma (IMMUNO-TH)
Study Overview
Status
Intervention / Treatment
Detailed Description
Open-label multicentric single-arm two-stage phase 2 trial. Population: Adult LT patients with advanced HCC recurrence with indication to systemic treatment Primary objective: To study the safety (ACR on histology) at 6 months of the first-line Atezo-Beva combination in LT patients with recurrent HCC in association with a standardized immunosuppressive treatment to prevent the risk of liver graft rejection.
Primary endpoint: Rate of Acute cellular rejection (ACR) (defined by a Histological Banff score ≥ 5) at 6 months (confirmed by an external expert center).
Secondary objective:
To study the safety (ACR on histology) at 24 months and at the end of Atezo-Beva treatment in LT patients with recurrent HCC in association with a standardized immunosuppressive treatment to prevent the risk of liver graft rejection.
- To assess the efficacy and tolerance of first-line Atezo-Beva combination in LT patients with advanced HCC in association with a standardized immunosuppressive treatment to prevent the risk of ACR based on:
- the Progression Free Survival (PFS)
- the Overall survival (OS)
- the objective response rate (ORR) (complete and partial response)
- the duration of response
- the quality of life of the patients under Atezo-Beva treatment
- To compare the efficacy (OS and PFS) of LT patients treated by Atezo- Beva treatment to an historical retrospective cohort of LT patients already available treated by TKI as first line (external arm comparison)
- To assess the adverse events related to Atezo-Beva treatment in LT patients with recurrent advanced HCC.
- To assess the evolution of the level of donor specific antibodies (DSA) during Atezo-Beva treatment and its association with ACR, PFS and OS.
Translational research/ancillary studies:
- To assess the association before the first injection between the risk of ACR, PFS, OS and side effects and
- the "Immunome" imaging on tumor sample and non-tumoral liver sample to quantify and regionalize immune populations on pathology (Multispectral Imaging, Mantra)
- the Leukocyte DNA analysis to identify constitutional genetic variants
- To assess the association before the first injection or just before the second injection and at 3 months between the risk of ACR, PFS, OS and side effects and
- the "immunomonitoring" on blood sample (frequency and/or the phenotype of circulating immune cells)
- the presence of tumors cells (liquid biopsies)
- the presence of circulating tumor DNA and the type of mutations
- the presence of circulating proteins
- the profile of circulating exosomes
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Manon Allaire, MD
- Phone Number: +33 142127064
- Email: manon.allaire@aphp.fr
Study Contact Backup
- Name: Anne Bissery
- Phone Number: +33 142162432
- Email: anne.bissery@aphp.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All patients over 18 and under 90 years old:
- who underwent LT more than 6 months ago (to prevent the higher risk of ACR which exists within the first months after LT and to deal with populations with a lowered immunosuppressive regimen long after LT)
- with HCC recurrence diagnosis according to the EASL diagnostic criteria (33)
- with advanced HCC not accessible to surgery and locoregional treatment
- with at least one measurable untreated lesion
- With a proposal for Atezo-Beva in first line treatment made in a multidisciplinary meeting
- ECOG Performance Status of 0 or 1
- For women of childbearing potential and men: agreement to remain abstinent
- Child-Pugh class A
Exclusion Criteria:
- History of ACR within 3 months before starting Atezo-Beva treatment
- Banff score for acute cellular rejection ≥ 3 on liver biopsy performed before the initiation of the treatment
- Pregnant or breastfeeding woman
- Patient not affiliated to a beneficiary or entitled social security scheme or to the PUMA
- Patient not having signed consent
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT-scan
- History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high-risk for bleeding
- A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment.
- Inadequately controlled arterial hypertension
- Prior history of hypertensive crisis or hypertensive encephalopathy
- History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction including sub-occlusive disease related to the underlying disease or requirement for routine parenteral hydration
- Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Atezo-Beva combination
first-line Atezo-Beva combination in LT patients with advanced HCC in association with a standardized immunosuppressive treatment to prevent the risk of acute cellular rejection
|
Atezolizumab-Bevacizumab every 3 weeks until progression or side effects in combination with Standardized immunosuppressive treatment: Tacrolimus (objective 5-7 ng/ml) Mycophenolate Mofetil 1000 mg per day Corticosteroids at least 5 mg per day Everolimus will be continued if already started before the inclusion (objective 5-7 ng/ml). If everolimus has not been started prior to inclusion, do not start it, but adopt the following protocol: corticoids + Tacrolimus + Cellcept. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Acute cellular rejection (ACR) (defined by a Histological Banff score ≥ 5) at 6 months (confirmed by an external expert center)
Time Frame: 6 months
|
To study the safety (ACR on histology) at 6 months of the first-line Atezo-Beva combination in LT patients with recurrent HCC in association with a standardized immunosuppressive treatment to prevent the risk of liver graft rejection
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Acute Cellular Rejection (ACR) at 24 months
Time Frame: 24 months
|
Rate of ACR (defined by a Histological Banff score ≥ 5) at 24 months (confirmed by a second external expert center.
|
24 months
|
Rate of Acute Cellular Rejection (ACR) at the end of Atezo-Beva treatment
Time Frame: at the end of treatment
|
Rate of ACR (defined by a Histological Banff score ≥ 5) at 24 months and at the end of Atezo-Beva treatment (confirmed by a second external expert center.
|
at the end of treatment
|
Progression Free Survival (PFS)
Time Frame: between the inclusion and 24 months after the last inclusion
|
The Progression Free Survival (PFS) is defined as the time from inclusion to disease progression according to RECIST 1.1 on imaging (CT-scan) performed every 3 months or death from any cause, whichever occurred first.
|
between the inclusion and 24 months after the last inclusion
|
Overall survival (OS)
Time Frame: between the inclusion and 24 months after the last inclusion
|
The Overall survival (OS) defined by the time from inclusion to death from any cause
|
between the inclusion and 24 months after the last inclusion
|
Objective Response Rate (ORR)
Time Frame: 12 months
|
The Objective Response Rate (ORR) at 12 months is defined as the percentage of patients with a confirmed complete or partial response according to RECIST 1.1 criteria on imaging (CT-scan) performed every 3 months.
|
12 months
|
Duration of response
Time Frame: between the inclusion and 24 months after the last inclusion
|
The Duration of response is defined by the time from first documentation of complete or partial response to disease progression or death according to RECIST 1.1 criteria on imaging (CT-scan) performed every 3 months.
|
between the inclusion and 24 months after the last inclusion
|
Time to deterioration of quality of life
Time Frame: between the inclusion and 24 months after the last inclusion
|
The time to deterioration of quality of life is defined as the time from inclusion to the first deterioration of quality of life as reported by the patient, with deterioration defined as a decrease from baseline of 10 points or more on the EORTC QLQ-C30 maintained for two consecutive assessments or a decrease of 10 points or more in one assessment followed by death from any cause within 3 weeks.
Each quality of life evaluation will be reported by the patient using EORTC QLQ-C30 score fill formed every 6 months until 24 months after the initiation of the treatment.
|
between the inclusion and 24 months after the last inclusion
|
Type, frequency and severity of adverse events and serious adverse events
Time Frame: between the inclusion, at the end of Atezo-Bev treatment and up to 24 months
|
They will be assessed on the basis of the nature, frequency and severity of adverse events according to NCI Common Terminology Criteria for Adverse Events, version 4.0.
The management of side effects usually observed under immunotherapy will be managed according to the American Society of Clinical Oncology Clinical Practice Guidelines
|
between the inclusion, at the end of Atezo-Bev treatment and up to 24 months
|
Donor Specific Antibodies (DSA) median
Time Frame: baseline and at Day 21, 3 Months 6 Months , 12 Months , 18 Months , 24 Months
|
DSA will be assessed and correlation to ACR, the PFS and OS will be evaluated
|
baseline and at Day 21, 3 Months 6 Months , 12 Months , 18 Months , 24 Months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP230899
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplant
-
Oslo University HospitalSouth-Eastern Norway Regional Health AuthorityNot yet recruitingLiver Metastases | Liver Transplant; Complications | Liver Cancer | Transplant | Transplant; Failure, Liver | Transplant; Complication, Rejection | Transplant Dysfunction
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)TerminatedLiver Transplant | Kidney TransplantUnited States
-
Astellas Pharma Europe Ltd.CompletedLiver Transplant | Kidney TransplantItaly, Spain, Belgium, Germany, Latvia, Canada, Korea, Republic of, Czechia, Austria, Finland, Belarus, Estonia, France, Hungary, Ireland, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Sweden, Switzerland, United...
-
University Health Network, TorontoNot yet recruitingSolid Organ Transplant | Liver Transplant | Kidney Transplant | Heart Transplant
-
Memorial Bahçelievler HospitalCompletedLiver Diseases | Liver Failure | Liver Cirrhosis | Liver Transplant; Complications | Liver Transplant Rejection | Organ Transplant Failure or Rejection | Liver Transplant FailureTurkey
-
University of FloridaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedLiver Transplant | Kidney TransplantUnited States, Singapore
-
National Taiwan University HospitalUnknownRenal Transplant | Liver TransplantTaiwan
-
Paragonix TechnologiesEnrolling by invitationLiver Diseases | Liver Transplant Disorder | Liver Dysfunction | Liver Transplant RejectionUnited States
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Clinical Trials in Organ Transplantation...CompletedLiver Transplant Recipient | Living Donor (of the Respective Liver Transplant Recipient)United States
-
PilloxaTerminatedLiver Transplant; Complications | Kidney Transplant; ComplicationsSweden
Clinical Trials on Systemic therapy
-
Henan Cancer HospitalWithdrawnStage IV Breast CancerChina
-
Vastra Gotaland RegionNot yet recruitingNon Small Cell Lung CancerSweden
-
Károli Gáspár University of the Reformed Church...University of TorontoCompletedMild to Moderate Psychopathological SymptomsHungary
-
Institut Mutualiste MontsourisFondation de l'Avenir; U1178 INSERM; PHRC Interrégionnal 2015; Fondation Sandrine... and other collaboratorsRecruitingAnorexia NervosaFrance
-
Javier Hidalgo TallónSociedad Española de OzonoterapiaUnknown
-
Neuropsychiatric Hospital dr Ivan BarbotActive, not recruitingDepression | Anxiety | Mental Health Disorder | Post Traumatic Stress Disorder | Panic DisorderCroatia
-
Jeroen Bosch ZiekenhuisBorstkanker Onderzoek Groep; Comprehensive Cancer Centre The NetherlandsTerminatedMetastatic Breast CancerNetherlands
-
M.D. Anderson Cancer CenterCompletedProstate CancerUnited States, Canada
-
University of ArizonaInari MedicalRecruitingPulmonary Hypertension | Pulmonary Embolism | Chronic Thromboembolic Pulmonary HypertensionUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisUnknown